Company profile · Biotech & medical
PharmaEssentia
藥華醫藥股份有限公司 · 6446
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
PharmaEssentia is engaged in the research, development, clinical trials, production, product sales, and market expansion of new biopharmaceutical drugs in the hematology and oncology fields.[1]
The company's main product is Ropeg, which is used for treating polycythemia vera and has received regulatory approval for sale in the European Union, United States, Japan, South Korea, and Taiwan.[2]
PharmaEssentia sells its products globally through direct sales or licensing agreements with partners such as AOP, Pint-Pharma GmbH, and Forus Therapeutics Inc.[2]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$2.8bn | +102.0% | +7.6% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$1.7bn |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | PharmaEssentia Corp. |
|---|---|
| Chinese name | 藥華醫藥股份有限公司 |
| Stock code | 6446 (TWSE) |
| Industry | Biotech & medical |
| Founded | 09 May 2000 |
| Listed | 25 Jan 2024 |
| Paid-in capital | NT$4.2bn |
| Chairman | 詹青柳 |
| President | 黃正谷 |
| Headquarters | 3 F., No. 3, Park St., Nangang Dist. Taipei City 115603, Taiwan |
| Website | http://www.PharmaEssentia.com |
| Official business description | 從事新藥之研究、開發、生產與銷售 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- MOPS 公司基本資料 藥華醫藥股份有限公司 · mops · retrieved 03 Nov 2026
- Annual report 2025 (English), business scope · annual_report · retrieved 03 Nov 2026
Using it at work? Join the team-plan waiting list